Skip to main content
SpringerLink
Log in
Book cover

Adult and Pediatric Neuromodulation pp 25–46Cite as

Sacral Neuromodulation for Overactive Bladder

  • Chapter
  • First Online:

Abstract

Overactive bladder (OAB) is a urologic condition that negatively impacts quality of life. Sacral neuromodulation (SNM) is a safe and effective treatment option that has been studied extensively in patients with severe and refractory OAB. SNM significantly reduces urgency, frequency, and incontinence while also improving quality of life. Although SNM is not currently indicated for the treatment of OAB symptoms due to neurologic disease, recent literature suggests that these patients may also benefit from SNM. Other areas requiring further investigation include reduction of adverse events associated with SNM and the overall cost benefit ratio of SNM.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

AUA:

American Urologic Association

BoNT-A:

Botulinum Toxin A

CIC:

Clean intermittent catheterization

EAU:

European Urologic Association

FDA:

Food and drug administration

LUTD:

Lower urinary tract dysfunction

LUTS:

Lower urinary tract symptoms

MRI:

Magnetic resonance imaging

MS:

Multiple sclerosis

OAB:

Overactive bladder

OMT:

Optimal medical therapy

PTNS:

Percutaneous tibial nerve stimulation

QAYL:

Quality adjusted life years

QoL:

Quality of life

SNM:

Sacral neuromodulation

References

  1. Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, Chen CI, Quentin Clemens J. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn. 2013;32:230–7.

    Article  PubMed  Google Scholar 

  2. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.

    CAS  PubMed  Google Scholar 

  3. Reynolds WS, Fowke J, Dmochowski R. The burden of overactive bladder on US Public Health. Curr Bladder Dysfunct Rep. 2016;11(1):8–13.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Comorbidities and personal burden of urgency urinary incontinence: a systematic review. Int J Clin Pract. 2013;67(10):1015–33.

    Article  CAS  PubMed  Google Scholar 

  5. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–78.

    Article  PubMed  Google Scholar 

  6. Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014;65(1):79–95.

    Article  PubMed  Google Scholar 

  7. Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology. 2012;80(1):90–6.

    Article  PubMed  Google Scholar 

  8. Birder L, Andersson KE. Urothelial signaling. Physiol Rev. 2013;93:653–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Birder L, de Groat W, Mills I, Morrison J, Thor K, Drake M. Neural control of the lower urinary tract: peripheral and spinal mechanisms. Neurourol Urodyn. 2010;29:128–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Andersson KE, McCloskey KD. Lamina propria: the functional center of the bladder? Neurourol Urodyn. 2014;33:9–16.

    Article  PubMed  Google Scholar 

  11. Janig W, Morrison JF. Functional properties of spinal visceral afferents supplying abdominal and pelvic organs, with special emphasis on visceral nociception. Prog Brain Res. 1986;67:87–114.

    Article  CAS  PubMed  Google Scholar 

  12. Habler HJ, Janig W, Koltzenburg M. Activation of unmyelinated afferent fibres by mechanical stimuli and inflammation of the urinary bladder in the cat. J Physiol. 1990;425:545–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Fall M, Lindstrom S, Mazieres L. A bladder-to-bladder cooling reflex in the cat. J Physiol. 1990;427:281–300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Juszczak K, Ziomber A, Wyczolkowski M, Thor PJ. Urodynamic effects of the bladder C-fiber afferent activity modulation in chronic model of overactive bladder in rats. J Physiol Pharmacol. 2009;60:85–91.

    CAS  PubMed  Google Scholar 

  15. de Groat WC. A neurologic basis for the overactive bladder. Urology. 1997;50:36–52.

    Article  PubMed  Google Scholar 

  16. Brading AF, Turner WH. The unstable bladder: towards a common mechanism. Br J Urol. 1994;73:3–8.

    Article  CAS  PubMed  Google Scholar 

  17. Brading AF. A myogenic basis for the overactive bladder. Urology. 1997;50:57–67.

    Article  CAS  PubMed  Google Scholar 

  18. Mills IW, Greenland JE, McMurray G, McCoy R, Ho KM, Noble JG, Brading AF. Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. J Urol. 2000;163:646–51.

    Article  CAS  PubMed  Google Scholar 

  19. Drake MJ, Mills IW, Gillespie JI. Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet. 2001;358:401–3.

    Article  CAS  PubMed  Google Scholar 

  20. Coolsaet BL, Van Duyl WA, Van Os-Bossagh P, De Bakker HV. New concepts in relation to urge and detrusor activity. Neurourol Urodyn. 1993;12:463–71.

    Article  CAS  PubMed  Google Scholar 

  21. Sukhu T, Kennelly MJ, Kurpad R. Sacral neuromodulation in overactive bladder: a review and current perspectives. Res Rep Urol. 2016;8:193–9.

    PubMed  PubMed Central  Google Scholar 

  22. Yoshimura N, de Groat WC. Patch clamp analysis of afferent and efferent neurons that innervated the urinary bladder of the rat. Soc Neurosci Abstr. 1992;18:127.

    Google Scholar 

  23. Yoshimura N, de Groat WC. Neural control of the lower urinary tract. Int J Urol. 1997;4:111.

    Article  CAS  PubMed  Google Scholar 

  24. Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am. 2005;32:11–8.

    Article  PubMed  Google Scholar 

  25. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, Das AK, Foster HE Jr, Scarpero HM, Tessier CD, Vasavada SP, American Urological Association. Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction: diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2455–63.

    Article  PubMed  Google Scholar 

  26. Fantl JA, Wyman JF, McClish DK, Harkins SW, Elswick RK, Taylor JR, Hadley EC. Efficacy of bladder training in older women with urinary incontinence. JAMA. 1991;265(5):609–13.

    Article  CAS  PubMed  Google Scholar 

  27. Jarvis GJ. A controlled trial of bladder drill and drug therapy in the management of detrusor instability. Br J Urol. 1981;53(6):565–6.

    Article  CAS  PubMed  Google Scholar 

  28. Goode PS, Burgio KL, Locher JL, Umlauf MG, Lloyd LK, Roth DL. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J Am Geriatr Soc. 2002;50(5):808–16.

    Article  PubMed  Google Scholar 

  29. Kaya S, Akbayrak T, Beksac S. Comparison of different treatment protocols in the treatment of idiopathic detrusor overactivity: a randomized controlled trial. Clin Rehabil. 2011;25(4):327–38.

    Article  PubMed  Google Scholar 

  30. Arruda RM, Castro RA, Sousa GC, Sartori MG, Baracat EC, Girão MJ. Prospective randomized comparison of oxybutynin, functional electrostimulation, and pelvic floor training for treatment of detrusor overactivity in women. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(8):1055–61.

    Article  PubMed  Google Scholar 

  31. Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, Candib D. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA. 1998;280(23):1995–2000.

    Article  CAS  PubMed  Google Scholar 

  32. Song C, Park JT, Heo KO, Lee KS, Choo MS. Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study. J Korean Med Sci. 2006;21(6):1060–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Wyndaele JJ, Goldfischer ER, Morrow JD, Gong J, Tseng LJ, Guan Z, Choo MS. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract. 2009;63(4):560–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Zinner N, Noe L, Rasouliyan L, Marshall T, Seifeldin R. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER. Curr Med Res Opin. 2008;24(6):1583–91.

    Article  CAS  PubMed  Google Scholar 

  35. Zinner N, Kobashi KC, Ebinger U, Viegas A, Egermark M, Quebe-Fehling E, Koochaki P. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. Int J Clin Pract. 2008;62(11):1664–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Hussein M, Fanning K, Trocio JN, Brubaker L. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276–82.

    Article  PubMed  Google Scholar 

  37. Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767–74.

    Article  CAS  PubMed  Google Scholar 

  38. Dmochowski RR, Sand PK, Zinner NR, Staskin DR. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology. 2008;71(3):449–54.

    Article  PubMed  Google Scholar 

  39. Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, Stolzel M, Martin N, Gunther A, Van Kerrebroeck P. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82(2):313–20.

    Article  PubMed  Google Scholar 

  40. Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–95.

    Article  CAS  PubMed  Google Scholar 

  41. Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, Dorrepaal C, Martin N. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305.

    Article  CAS  PubMed  Google Scholar 

  42. Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Ther Adv Drug Saf. 2016;7(5):204–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Perk S, Wielage RC, Campbell NL, Klein TM, Perkins A, Posta LM, Yuran T, Klein RW, Ng DB. Estimated budget impact of increased use of mirabegron, a novel treatment for overactive bladder. J Manag Care Spec Pharm. 2016;22(9):1072–8.

    Article  PubMed  Google Scholar 

  44. Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J, Pelvic Floor Disorders Network. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180(1):217–22.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol. 2009;181(6):2608–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn. 2011;30(7):1242–8.

    PubMed  Google Scholar 

  47. Orasanu B, Mahajan S. The use of botulinum toxin for the treatment of overactive bladder syndrome. Indian J Urol. 2013;29(1):2–11.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Kuo Y, Kuo H. Adverse events of intravesical onabotulinumtoxinA injection between patients with overactive bladder and interstitial cystitis—different mechanisms of action of Botox on bladder dysfunction? Toxins (Basel). 2016;8(3).

    Article  PubMed Central  CAS  Google Scholar 

  49. Peters KM, Macdiarmid SA, Wooldridge LS, Leong FC, Shobeiri SA, Rovner ES, Siegel SW, Tate SB, Jarnagin BK, Rosenblatt PL, Feagins BA. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055–61.

    Article  CAS  PubMed  Google Scholar 

  50. Sancaktar M, Ceyhan ST, Akyol I, Muhcu M, Alanbay I, Mutlu Ercan C, Atay V. The outcome of adding peripheral neuromodulation (Stoller afferent neuro-stimulation) to anti-muscarinic therapy in women with severe overactive bladder. Gynecol Endocrinol. 2010;26(10):729–32.

    Article  PubMed  Google Scholar 

  51. Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 2012;31(8):1206–16.

    Article  CAS  PubMed  Google Scholar 

  52. Siegel SW, Catanzaro F, Dijkema HE, Elhilali MM, Fowler CJ, Gajewski JB, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology. 2000;4(56):87–91.

    Article  Google Scholar 

  53. Everaert K, Kerckhaert W, Caluwaerts H. A prospective randomized trial comparing the 1-stage with the 2-stage implantation of a pulse generator in patients with pelvic floor dysfunction selected for sacral nerve stimulation. Eur Urol. 2004;45:649–54.

    Article  CAS  PubMed  Google Scholar 

  54. National Guideline Clearinghouse (NGC). Guideline summary: Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2014 May 01. [cited 2016 Dec 01]. https://www.guideline.gov

  55. Tanagho EA, Schmidt RA. Bladder pacemaker: scientific basis and clinical future. Urology. 1982;20(6):614–9.

    Article  CAS  PubMed  Google Scholar 

  56. Schmidt RA, Jonas U, Oleson KA, Jankgnegt RA, Hassouna MM, Siegel SW, et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol. 1999;162(2):352–7.

    Article  CAS  PubMed  Google Scholar 

  57. Scheepens WA, Weil EH, van Koeveringe GA, Rohrmann D, Hedlund HE, Schurch B, et al. Buttock placement of the implantable pulse generator: a new implantation technique for sacralneuromodulation—a multicenter study. Eur Urol. 2001;40(4):434–8.

    Article  CAS  PubMed  Google Scholar 

  58. Hetzer FH. Fifteen years of sacral nerve stimulation: from an open procedure to a minimally invasive technique. Color Dis. 2011;13(2):1–4.

    Article  Google Scholar 

  59. Spinelli M, Giardiello G, Arduini A, Van den Hombergh U. New percutaneous technique of sacral nerve stimulation has high initial success rate: preliminary results. Eur Urol. 2003;43(1):70–4.

    Article  PubMed  Google Scholar 

  60. Hijaz A, Vasavada S. Complications and troubleshooting of sacral neuromodulation therapy. Urol Clin North Am. 2005;32:65–9.

    Article  PubMed  Google Scholar 

  61. Siddiqui NY, JM W, Amundsen CL. Efficacy and adverse events of sacral nerve stimulation for overactive bladder: a systematic review. Neurourol Urodyn. 2010;29(Suppl 1):S18–23.

    Article  PubMed  Google Scholar 

  62. Peeters K, Sahai A, De Ridder D, Van Der Aa F. Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction. BJU Int. 2014;113(5):789–94.

    Article  PubMed  Google Scholar 

  63. Bladder and Bowel Community. Sacral Nerve Stimulation (Sacral Neuromodulation Therapy); [cited 2017 Jan 22]. https://www.bladderandbowelfoundation.org.

  64. Amundsen CL, Romero AA, Jamison MG, Webster GD. Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure? Urology. 2005;66(4):746–50.

    Article  PubMed  Google Scholar 

  65. Elkelini MS, Hassouna MM. Safety of MRI at 1.5Tesla in patients with implanted sacral nerve neurostimulator. Eur Urol. 2006;50(2):311–6.

    Article  PubMed  Google Scholar 

  66. Chermansky CJ, Krlin RM, Holley TD, Woo HH, Winters JC. Magnetic resonance imaging following InterStim®: an institutional experience with imaging safety and patient satisfaction. Neurourol Urodyn. 2011;30(8):1486–8.

    Article  PubMed  Google Scholar 

  67. Alsyouf M, Keheila M, Marinone M. Magnetic resonance imaging of the ankle performed on an InterStim patient. Can J Urol. 2016;23(1):8168–70.

    PubMed  Google Scholar 

  68. MRI guidelines for InterStim Therapy Neurostimulation Systems. 1st ed. Medtronic, 2017; [2017 Jan 15]. https://professional.medtronic.com.

  69. Yaiesh SM, Al-Terki AE, Al-Shaiji TF. Safety of sacral nerve stimulation in pregnancy: a literature review. Neuromodulation. 2016;19:770–9.

    Article  PubMed  Google Scholar 

  70. Noblett K, Benson K, Kreder K. Detailed analysis of adverse events and surgical interventions in a large prospective trial of sacralneuromodulation therapy for overactive bladder patients. Neurourol Urodyn. https://doi.org/10.1002/nau.23076. [Epub ahead of print].

  71. Marcelissen TA, Leong RK, de Bie RA. Long-term results of sacral neuromodulation with the tined lead procedure. J Urol. 2010;184:1997–2000.

    Article  PubMed  Google Scholar 

  72. Wein AJ, Kavoussi LR, Partin AW, Peters CA. Campbell-Walsh Urology. 12th ed. Philadelphia, PA: Elsevier; 2016.

    Google Scholar 

  73. Groenendijk PM, Lycklama à Nyeholt AA, Heesakkers JP, van Kerrebroeck PE, Hassouna MM, Gajewski JB. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU Int. 2008;101(3):325–9.

    Article  PubMed  Google Scholar 

  74. Aboseif S, Tamaddon K, Chalfin S, Freedman S, Kaptein J. Sacral neuromodulation as an effective treatment for refractory pelvic floor dysfunction. Urology. 2002;60(1):52–6.

    Article  PubMed  Google Scholar 

  75. Hassouna MM, Siegel SW, Nyeholt AA. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol. 2000;163:1849–54.

    Article  CAS  PubMed  Google Scholar 

  76. Weil EH, Ruiz-Cerdá JL, Eerdmans PH. Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. Eur Urol. 2000;37(2):161–71.

    Article  CAS  PubMed  Google Scholar 

  77. van Kerrebroeck EV, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective worldwide clinical study. J Urol. 2007;178:2029–34.

    Article  PubMed  Google Scholar 

  78. Groen J, Blok BF, Bosch JL. Sacral neuromodulation as treatment for refractory idiopathic urge urinary incontinence: 5-year results of a longitudinal study in 60 women. J Urol. 2011;186(3):954–9.

    Article  PubMed  Google Scholar 

  79. Cardarelli S, D'Elia C, Cerruto MA, Curti P, Ostardo E, Signorello D, et al. Efficacy of sacral neuromodulation on urological diseases: a multicentric research project. Urologia. 2012;79(2):90–6.

    Article  PubMed  Google Scholar 

  80. Moon KH, Han JY, Kim JH, Lee HN, Lee KS, Lee JG, SJ O, Yoon HN, Choo MS. Prospective trial of sacral neuromodulation for refractory overactive bladder syndrome in Korean patients. Low Urin Tract Symptoms. 2013;6(3):175–9.

    Article  PubMed  Google Scholar 

  81. Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34(3):224–30.

    Article  PubMed  Google Scholar 

  82. Leong RK, Marcelissen TA, Nieman FH. Satisfaction and patient experience with sacral neuromodulation: results of a single center sample survey. J Urol. 2011;185(2):588–92.

    Article  PubMed  Google Scholar 

  83. Kessler TM, La Framboise D, Trelle S, et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol. 2010;58:865–74.

    Article  PubMed  Google Scholar 

  84. Tanagho EA, Schmidt RA, Orvis BR. Neural stimulation for control of voiding dysfunction: a preliminary report in 22 patients with serious neuropathic voiding disorders. J Urol. 1989;142:340–5.

    Article  CAS  PubMed  Google Scholar 

  85. Lombardi G, Del Popolo G. Clinical outcome of sacral neuromodulation in incomplete spinal cord injured patients suffering from neurogenic lower urinary tract symptoms. Spinal Cord. 2009;47(6):486–91.

    Article  CAS  PubMed  Google Scholar 

  86. Lombardi G, Nelli F, Mencarini M, Del Popolo G. Clinical concomitant benefits on pelvic floor dysfunctions after sacral neuromodulation in patients with incomplete spinal cord injury. Spinal Cord. 2011;49:629–36.

    Article  CAS  PubMed  Google Scholar 

  87. Chen G, Liao L. Sacral neuromodulation for neurogenic bladder and bowel dysfunction with multiple symptoms secondary to spinal cord disease. Spinal Cord. 2015;53:204–8.

    Article  PubMed  Google Scholar 

  88. Wöllner J, Krebs J, Pannek J. Sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction. Spinal Cord. 2016;54(2):137–40.

    Article  PubMed  Google Scholar 

  89. Minardi D, Muzzonigro G. Sacral neuromodulation in patients with multiple sclerosis. World J Urol. 2012;30:123–8.

    Article  PubMed  Google Scholar 

  90. Engeler DS, Meyer D, Abt D. Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series. BMC Urol. 2015;15:105.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Puccini F, Bhide A, Elneil S, Digesu GA. Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis. Int Urogynecol J. 2016;27(3):347–54.

    Article  PubMed  Google Scholar 

  92. Wallace PA, Lane FL, Noblett KL. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol. 2007;197(1):96.e1–5.

    Article  Google Scholar 

  93. Peters KM, Kandagatla P, Killinger KA, Wolfert C, Boura JA. Clinical outcomes of sacral neuromodulation in patients with neurologic conditions. Urology. 2013;81(4):738–43.

    Article  PubMed  Google Scholar 

  94. Al-zahrani AA, Elzayat EA, Gajewski JB. Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center. J Urol. 2011;185:981–6.

    Article  PubMed  Google Scholar 

  95. Spinelli M, Weil E, Ostardo E. New tined lead electrode in sacral neuromodulation: experience from a multicentre European study. World J Urol. 2005;23(3):225–9.

    Article  PubMed  Google Scholar 

  96. Peters KM, Carey JM, Konstandt DB. Sacral neuromodulation for the treatment of refractory interstitial cystitis: outcomes based on technique. Int Urogynecol J Pelvic Floor Dysfunct. 2003;14:223–8.

    Article  CAS  PubMed  Google Scholar 

  97. Scheepens WA, Van Koeveringe GA, De Bie RA, et al. Long-term efficacy and safety results of the two-stage implantation technique in sacral neuromodulation. BJU Int. 2002;90:840–5.

    Article  CAS  PubMed  Google Scholar 

  98. Medtronic: Manuals and Technical Resources; [cited 2017 Jan 15]. http://professional.medtronic.com/products/interstim-II-sacral-nerveneurostimulator/manuals-and-technical-resources/index.htm.

  99. Benninghoff D. Anatomy. Urban & Fischer Verlag: München; 2003.

    Google Scholar 

  100. Amend B, Matzel KE, Abrams P, de Groat WC, Sievert KD. How does neuromodulation work. Neurourol Urodyn. 2011;30(5):762–5.

    Article  PubMed  Google Scholar 

  101. Swinn MJ, Schott GD, Oliver SE. Leg pain after sacral neuromodulation: anatomical considerations. BJU Int. 1999;84:1113–5.

    Article  CAS  PubMed  Google Scholar 

  102. Cohen BL, Tunuguntla HS, Gousse A. Predictors of success for first stage neuromodulation: motor versus sensory response. J Urol. 2006;175:2178–80.

    Article  PubMed  Google Scholar 

  103. Govaert B, Melenhorst J, Van Gemert WG, Baeten CG. Can sensory and/or motor reactions during percutaneous nerve evaluation predict outcome of sacral nerve modulation? Dis Colon Rectum. 2009;52:1423–6.

    Article  CAS  PubMed  Google Scholar 

  104. Candiotti KA, Bergese SD, Bokesch PM, Feldman MA, Wisemandle W, Bekker AY. Monitored anesthesia care with dexmedetomidine: a prospective, randomized, double-blind, multicenter trial. MAC Study Group. Anesth Analg. 2010;110(1):47–56.

    Article  CAS  PubMed  Google Scholar 

  105. Jacobs SA, Lane FL, Osann KE, Noblett KL. Randomized prospective crossover study of InterStim lead wire placement with curved versus straight stylet. Neurourol Urodyn. 2014;33(5):488–92.

    Article  PubMed  Google Scholar 

  106. Onukwugha E, Zuckerman I, et al. The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care. 2009;15(4 Suppl):S90–7.

    PubMed  Google Scholar 

  107. Aboseif SR, Kim DH, Rieder JM. Sacral neuromodulation: cost considerations and clinical benefits. Urology. 2007;70(6):1069–74.

    Article  PubMed  Google Scholar 

  108. Siddiqui NY, Amundsen CL, Visco AG, Myers ER, Wu JM. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol. 2009;182(6):2799–804.

    Article  PubMed  Google Scholar 

  109. Autiero SW, Hallas N, Betts CD, Ockrim JL. The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK. BJU Int. 2015;116(6):945–54.

    Article  CAS  PubMed  Google Scholar 

  110. Arlandis S, Castro D, Errando C, Fernández E, Jiménez M, González P, et al. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder. Value Health. 2011;14(2):219–28.

    Article  PubMed  Google Scholar 

  111. Bertapelle MP, Vottero M, Popolo GD, Mencarini M, Ostardo E, Spinelli M, et al. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System. World J Urol. 2015;33(8):1109–17.

    Article  CAS  PubMed  Google Scholar 

  112. Hassouna MM, Sadri H. Economic evaluation of sacral neuromodulation in overactive bladder: a Canadian perspective. Can Urol Assoc J. 2015;9(7–8):242–7.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery, University of Arizona College of Medicine, Tucson, AZ, USA

    John R. Michalak, Sunchin Kim, Joel T. Funk & Christian O. Twiss

Authors
  1. John R. Michalak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sunchin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joel T. Funk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christian O. Twiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian O. Twiss .

Editor information

Editors and Affiliations

  1. Department of Urology, Oakland University William, Beaumont School of Medicine, Royal Oak, Michigan, USA

    Jason P. Gilleran

  2. Section of Urology, Nationwide Children’s Hospital and The Ohio State Wexner Medical Center, Columbus, Ohio, USA

    Seth A. Alpert

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Michalak, J.R., Kim, S., Funk, J.T., Twiss, C.O. (2018). Sacral Neuromodulation for Overactive Bladder. In: Gilleran, J., Alpert, S. (eds) Adult and Pediatric Neuromodulation . Springer, Cham. https://doi.org/10.1007/978-3-319-73266-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-73266-4_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-73265-7

  • Online ISBN: 978-3-319-73266-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation